P-48 HEPATITIS DELTA: THE MOST SEVERE OF ALL VIRAL HEPATITIS

Introduction

500,000 to 1.2 million deaths are speculated annually from complications of hepatitis B. The hepatitis Delta virus (HDV) also represents an important public health problem in endemic areas.

Objective

To analyze the clinical and laboratory characteristics at the first consultation of HBV and HBV/HDV patients.

Methods

Retrospective study (2017 and 2018) of 324 records of HBV and HBV/HDV patients at Research Center for Tropical Medicine of Rondônia. Project approved by the Research Ethics Committee. For statistical analysis, SPSS® version 25.0.

Results

A total of 324 patients were included, 302 (93.2%) were HBV and 22 were (6.7%) HBV/HDV. At the first consultation, 16.2% of the HBV showed signs of chronic liver disease, while in the HBV/HDV patients, 59.1% (p <0.0001). Signs of portal hypertension were present in 7.9% of HBV (splenomegaly in 5.6%) and in 54.5% of HBV/HDV patients (splenomegaly in 45.5%, p <0.0001). Ascites was seen in almost one third of those co-infected (27.3%). In laboratory analyzes, 6.4% of HBV patients had a total of bilirubin greater than 1.2 mg/dL, among those co-infected (45.5%, p <0.0001). Albumin was less than 3.5g/dL in 8.4% of the HBV and in 42.8% (p <0.0001) of the HBV/HDV patients. Alfafetoprotein was greater than 10UI/mL in 9.7% of the monoinfected and in 18.2% (p: 0.268) of the HBV/HDV patients.

Conclusion

Coinfected patients presented a more serious condition in the first consultation, with signs of portal hypertension and decompensated liver disease, reinforcing HDV as the most severe and rapidly progressive of all viral hepatitis.